Search Results
Nov 25, 2025, 10:06 ET Innova Therapeutics impulsará un nuevo tratamiento contra el cáncer con la adquisición de Enci Therapeutics
múltiples efectos antitumorales, incluyendo una potente reducción de la carga tumoral en tumores primarios y metastásicos, una menor expresión de CD38 y PD-1 en los linfocitos infiltrantes de tumores (TIL), la inhibición de la angiogénesis y un aumento del interferón gamma (IFNγ) en los macrófagos asociados
More news about: Innova Therapeutics
Nov 25, 2025, 08:00 ET GV20 Therapeutics Announces Achievement of Milestone under Antibody-Drug Conjugate Collaboration with Mitsubishi Tanabe Pharma Corporation
anti-IGSF8 antibodies enhance NK cell cytotoxicity, dendritic cell antigen presentation, and T cell activation, both alone and in combination with anti-PD1. In an ongoing Phase 1/2 trial (
More news about: GV20 Therapeutics
Nov 24, 2025, 08:34 ET GlycoNex and Hokkaido University Hospital Launch Study to Advance Glycan-Directed ADC Development in Gastric Cancer
distribution of bLeB/Y expression in these Japanese gastric cancer patients and compare it to established clinical biomarkers, including HER2, CLDN18, PD-L1, and MMR. The goal is to better define the patient population most likely to benefit from GNX1021 treatment, ultimately enhancing the probability of
More news about: GlycoNex, Inc.
Nov 24, 2025, 07:00 ET Kelun-Biotech Announces Phase III Trial of Sac-TMT in Combination with KEYTRUDA® (pembrolizumab) as First-Line Treatment for PD-L1-Positive NSCLC Met Primary Endpoint
company's TROP2 ADC sacituzumab tirumotecan (sac-TMT, also known as SKB264/MK-2870), in combination with MSD's anti-PD-1 therapy KEYTRUDA®[1] (pembrolizumab), as a first-line treatment for PD-L1-positive advanced non-small cell lung cancer (NSCLC), has demonstrated a statistically significant and
More news about: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Nov 24, 2025, 07:00 ET BioLineRx Reports Third Quarter 2025 Financial Results and Provides Corporate Update
investigators for the study.The Phase 1 part of the trial aims to establish a maximum tolerated dose (MTD) and/or a recommended dose based on safety, PK/PD and preliminary efficacy.The Phase 2a expansion part of the trial is planned to include three population cohorts: (1) GLIX1 as monotherapy in
More news about: BioLineRx Ltd.
Nov 24, 2025, 02:11 ET Pin Therapeutics Initiates First-Patient Dosing of CK1α Degrader PIN-5018 in Phase 1 Trial
combination regimens. The Phase 1 study employs a dose-escalation design to assess safety, pharmacokinetics (PK), and target engagement/pharmacodynamics (PD). Pin Therapeutics also plans to expand development into additional indications.PIN-5018 Achieves Complete Response in ACC PDX
More news about: Pin Therapeutics
Nov 23, 2025, 18:30 ET 環旭電子助力客戶推出通過Intel® Evo™認證的Thunderbolt™ 5智慧型擴充基座
此智慧型擴充基座專為現代混合辦公與創作應用而打造，提供突破性頻寬、高效能電力供應與智慧化管理功能，協助使用者輕鬆將筆電升級為完整的桌上型工作站。產品採用Intel最新Thunderbolt™ 5技術，可提供高達120 Gbps的頻寬，相較前一代提升三倍效能，支援多螢幕輸出（最高可達三個8K 60Hz顯示器或雙4K高更新率顯示器）。產品同時具備跨作業系統相容性、PD 3.1快速充電（最高 180 W）與電弧保護設計，兼顧高效能與穩定性，滿足商務用戶、專業創作者與遊戲玩家的多元需求。據Grand View Research報告指出，全球擴充基座市場預估在2023至2030年間將以年均複合成長率6.1 %持續擴張。此成長動能主要來自
More news about: 環旭電子
Nov 20, 2025, 20:00 ET Fosun International Honored as "ESG Leading Enterprise" by Bloomberg Businessweek/Chinese Edition
and regions, benefiting more than 850,000 patients worldwide. Among them, HANSIZHUANG, an innovative anti-PD-1 monoclonal antibody independently developed by Fosun, is the world's first anti-PD-1 monoclonal antibody approved for the first-line treatment of small cell lung cancer (SCLC). It has been approved
More news about: Fosun
Nov 20, 2025, 13:16 ET Accord BioPharma, Inc. Announces FDA Approval of Denosumab Biosimilars OSVYRTI® (denosumab-desu) and JUBEREQ® (denosumab-desu)
multicenter study comparing PK/PD, efficacy and safety of OSVYRTI to Prolia in postmenopausal women with osteoporosis. The clinical study results demonstrated that OSVYRTI and its reference product, Prolia, are highly similar, and have no clinically meaningful differences in terms of PK, PD, safety and efficacy.2,4
More news about: Accord BioPharma
Nov 20, 2025, 07:00 ET SciNeuro Pharmaceuticals to Accelerate Novel LRRK2 Therapeutic (SNP614) Development with an Award from The Michael J. Fox Foundation
Mutations in the LRRK2 gene linked to Parkinson's disease were first discovered in 2004 and are now understood to be the most common cause of inherited PD. Built on MJFF's dedication to open science, LITE fosters international collaboration across more than 30 academic and clinical centers and more than
More news about: SciNeuro Pharmaceuticals
Nov 19, 2025, 21:56 ET Antengene Hosts 2025 R&D Day Showcasing Encouraging Clinical Data and Solid Progress with Investigational Programs
conjugate [ADC]), ATG-037 (oral CD73 small molecule inhibitor), and ATG-101 (PD-L1/4-1BB bispecific antibody). The company will also share the latest progress on ATG-125 (B7H3 x PD-L1 bispecific ADC): A B7H3 x PD-L1 targeted therapy featuring "IO + ADC" dual-effect molecules for the
More news about: Antengene Corporation Limited
Nov 19, 2025, 16:01 ET FDA GRANTS FULL APPROVAL TO AMGEN'S IMDELLTRA® IN EXTENSIVE STAGE SMALL CELL LUNG CANCER
tarlatamab in second-line ES-SCLC; DeLLphi-310, a Phase 1b study of tarlatamab in combination with YL201 with or without anti-programmed death ligand 1 (PD-L1) in patients with ES-SCLC; DeLLphi-311, a Phase 1b study of IMDELLTRA in combination with etakafusp alfa (AB248), a novel CD8+ T-cell selective interleukin-2
More news about: Amgen
Nov 19, 2025, 10:13 ET Aperture Therapeutics Announces Development Candidate Targeting CD33 to Restore Microglial Homeostasis in FTD and ALS
reduces chronic neuroinflammation. Elevated CD33 expression is consistently observed in patient tissues across ALS, FTD, AD, and Parkinson's disease (PD), underscoring the central role of microglial dysregulation in disease pathogenesis. "Although CD33 has long been recognized as
More news about: Aperture Therapeutics
Nov 18, 2025, 16:15 ET Kazia Therapeutics Achieves Initial iCR (Immune-Complete Response) in Metastatic TNBC and Delivers Q4 Business Update with Breakthroughs Across Breast Cancer, Immuno-Oncology, and GBM Regulatory Strategy
2. NDL2 PD-L1 Degrader Program: Advancing Toward IND-Enabling Studies anticipated in Early 2026 As announced in September 2025, Kazia entered into a collaboration and licensing agreement with QIMR Berghofer covering the first in class NDL2 PD-L1 degrader program.
More news about: Kazia Therapeutics Limited
Nov 18, 2025, 07:00 ET Genprex Announces U.S. Patent for Reqorsa® Gene Therapy in Combination with PD-L1 Antibodies to Treat Cancers
Tecentriq, a PD-L1 antibody, and this patent secures exclusivity for this drug combination for the treatment of cancer, preventing would-be competitors from making, using or selling this drug combination." Genprex has been granted patents for the use of REQORSA in combination with PD-L1
More news about: Genprex, Inc.
Nov 18, 2025, 07:00 ET Vincere Biosciences Awarded $5 Million from The Michael J. Fox Foundation to Advance Parkinson's Therapeutic Toward Clinical Trials
Mitochondrial dysfunction and impaired mitophagy are central features of PD pathophysiology. Mitophagy, the selective recycling of damaged mitochondria, is essential for maintaining neuronal health. In PD, this process is often compromised, leading to toxic buildup of defective mitochondria
More news about: Vincere Biosciences
Nov 18, 2025, 05:40 ET Oncology Molecular Diagnostics Market to Reach US$ 6.46 Billion by 2033, Driven by Precision Oncology, and Accelerating Biomarker-Based Therapies - According to DataM Intelligence
be one of the most dynamic areas, with molecular panels essential for identifying biomarkers such as EGFR mutations, ALK and ROS1 rearrangements, and PD-L1 expression supporting immunotherapy decisions.Colorectal and prostate cancers are increasingly reliant on genomic profiling to guide
More news about: DataM Intelligence 4 Market Research LLP
Nov 17, 2025, 11:27 ET St. Johns County Unanimously Approves 2026 Legislative Action Plan
County. Evacuation Routes – Requesting FDOT prioritize SR 206 improvements and complete the PD&E process for the SR 206/I-95 interchange to enhance evacuation capacity. Other Priority Corridors –
More news about: St. Johns County
Nov 17, 2025, 09:07 ET Atossa Highlights Emerging Opportunity for (Z)-Endoxifen in Duchenne Muscular Dystrophy, Including Symptomatic Female Carriers, Following Peer-Reviewed Publication and Scientific Presentation
small-molecule profile, exposure-guided strategy, and phase-appropriate GxP controls position it for a rigorous, stepwise program focused on safety, PK/PD, and functional endpoints. Our goal is to engage regulators early and, if data support, pursue rare-disease pathways that can responsibly accelerate
More news about: Atossa Therapeutics Inc
Nov 17, 2025, 08:49 ET Foldable, Featherlight, and Surprisingly Functional: Traveland Launches AuraOne 2.0, a Foldable Backpack Designed for Real-World Travel and Daily Carry
https://shorturl.at/pd26DPress kit & media:
More news about: Traveland
Nov 17, 2025, 08:00 ET Pioneering Neurologist and Advocate for Holistic Parkinson's Care, Bastiaan Bloem, MD, PhD, Receives the Robert A. Pritzker Prize
the nominee's complete body of work in the PD field with an emphasis on its impact on accelerating drug development; field-wide impact of the nominee's work; dedication to patient-relevant science; and influence on and encouragement of the next generation of PD investigators. The award itself is designed
More news about: The Michael J. Fox Foundation for Parkinson's Research
Nov 17, 2025, 06:00 ET Positive HERIZON-GEA-01 Phase 3 Results Support Ziihera® (zanidatamab-hrii) as HER2-Targeted Agent-of-Choice and Ziihera Combination Regimens as New Standard of Care in First-Line HER2-Positive Locally Advanced or Metastatic Gastroesophageal Adenocarcinoma
A PFS and OS benefit was observed in the Ziihera plus tislelizumab and chemotherapy arm versus the control arm in both PD-L1 positive and PD-L1 negative subgroups. Both Ziihera plus chemotherapy, and Ziihera plus tislelizumab and chemotherapy
More news about: Jazz Pharmaceuticals plc
Nov 17, 2025, 05:04 ET Research insight: Direct-to-device poised to redefine mobile-satellite integration
https://www.digitimes.com/news/a20251107PD205/leo-satellite-commercial-5g-spacex-technology.html
More news about: DIGITIMES
Nov 17, 2025, 02:00 ET Accession Therapeutics doses first patient in Phase 1 clinical trial of TROCEPT-01 (ATTR-01), a novel cancer immunotherapy
Company's lead investigational therapy utilises the company's proprietary TROCEPT platform to deliver a genetically encoded immune checkpoint inhibitor (anti-PD-L1) directly to tumour cells. This innovative approach enables cancer cells to locally produce and secrete therapeutic proteins within the tumour microenvironment,
More news about: Accession Therapeutics
Nov 13, 2025, 10:13 ET Ford Foundation Appoints Noorain Khan as Vice President and Chief Innovation Officer
scalable change." Khan began her career as an attorney at Wachtell, Lipton, Rosen & Katz in New York City. A Rhodes Scholar and PD Soros Fellow, she holds a JD from Yale Law School, an MPhil in Migration Studies from Oxford University, and a BA from Rice University.
More news about: Ford Foundation